Other biomarkers, while not specific to AD, indicate other neuropathological processes that contribute to dementia onset and clinical manifestation, namely neurodegeneration (e.g., total tau, t-tau; and neurofilament light chain, NfL) [9–11] and glial activation (e.g., glial fibrillary acidic protein, GFAP) [12]. This evidence concerns the gene MAPT and Alzheimer disease.